Alzheimer's Disease Clinical Trial
— EPMR-MAOfficial title:
Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease
Verified date | May 2023 |
Source | Rennes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Unrandomized, unblinded, monocentric comparative Functional Magnetic Resonance Imaging study.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 31, 2017 |
Est. primary completion date | December 31, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 75 Years |
Eligibility | Inclusion Criteria: Volunteers (pilot phase) - Aged 25 - 75 - French native speakers - Right-handed - Education level equal or superior to primary school leaving certificate - Free from any medical or psychiatric condition that may impact cognition - Having given written informed consent Volunteers (experimental phase) - Aged 60 - 75 - French native speakers - Right-handed - Education level equal or superior to primary school leaving certificate - Free from any medical or psychiatric condition that may impact cognition - Having given written informed consent AD-MCI participants - Aged 60 - 75 - French native speakers - Right-handed - Education level equal or superior to primary school leaving certificate - Fulfilling criteria for " AD-MCI " (Albert et al., 2011) - Have been seen in a memory medical center or in Memory Resources and Research Medical Center for cognitive symptoms - Free from any medical or psychiatric condition that may impact cognition - Able to understand and consent - Having given written informed consent Exclusion Criteria: MRI contraindications (all participants) - Claustrophobia - Wearing of any metal implant such as: - Heart pacemaker - Iron-magnetic surgical clips - Any metallic foreign body in the eye or brain Other criteria (all participants) - Significant history of neurological or psychiatric disorders - Ongoing medication that may affect cognitive performances - Sensory deficit that may interfere with the experimental design (e.g. uncorrected visual impairment) - Lack of sufficient cooperation during the cognitive tasks - Persons under major legal protection and/or deprived of liberty Other criteria (control participants) - Global cognitive impairment attested by Mattis Dementia Rating Scale or Mini-Mental State Examination, according to available normative data Other criteria (AD-MCI participants) - 7 items modified Hachinski ischemic score > 2 (Hachinski et al., 2012) - Dementia (McKahn, et al., 2011) |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Universitaire | Rennes |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
France,
Jonin PY, Duche Q, Bannier E, Corouge I, Ferre JC, Belliard S, Barillot C, Barbeau EJ. Building memories on prior knowledge: behavioral and fMRI evidence of impairment in early Alzheimer's disease. Neurobiol Aging. 2022 Feb;110:1-12. doi: 10.1016/j.neurob — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of recognition memory accuracy measures under the familiarity condition as compared with the novel condition in the AD-MCI group | 3 months | ||
Primary | Significant effect of the familiarity vs novelty condition on the pattern of % BOLD signal change in across the brain in the AD-MCI group | 3 months | ||
Secondary | Significant group effect on the pattern of % BOLD signal change in across the brain | 3 months | ||
Secondary | Predictive validity of the brain % BOLD signal change pattern for participants clinical status (i.e. controls vs. AD-MCI) | 3 months | ||
Secondary | Significant interaction between the kind of familiarity condition (i.e. novel, experimental or pre-experimental) and the estimates of recognition memory processes efficiency (i.e. respective contributions of recollection and familiarity, % correct) | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02094729 -
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |